Radiation and immunotherapy join forces against Hard-to-Treat liver metastases

NCT ID NCT06794086

First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time

Summary

This study tests whether combining a precise form of radiation (SBRT) with an immunotherapy drug (PD-1 monoclonal antibody) can help people whose colorectal cancer has spread to the liver and cannot be removed surgically. The trial enrolls adults aged 18 to 75 with a specific type of colorectal cancer (pMMR/MSS). The goal is to see if this combination shrinks tumors and improves outcomes, while monitoring for side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
PD-1 monoclonal antibody (a type of immunotherapy) plus stereotactic body radiation therapy (SBRT, a precise form of radiation)
What this could lead to
If successful, this combination could offer a new treatment option for people with colorectal cancer that has spread to the liver and cannot be removed by surgery, potentially shrinking tumors and improving survival.
What could go wrong
This is a small, early-phase study with only 24 participants, so results may not apply to everyone. The combination of radiation and immunotherapy can cause side effects such as fatigue, liver inflammation, or immune-related reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Sixth Affiliated Hospital, Sun Yat-sen University

    RECRUITING

    Guangzhou, Guangdong, 510065, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.